Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome

Psychoneuroendocrinology

Volumn 38, Issue 12, 2013, Pages 2983-2995

  Light, Kathleen C ^a   Agarwal, Neeraj ^a,b   Iacob, Eli ^a   White, Andrea T ^a,c   Kinney, Anita Y ^a,b   VanHaitsma, Timothy A ^c   Aizad, Hannah ^a   Hughen, Ronald W ^a   Bateman, Lucinda ^a,d   Light, Alan R ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Fatigue Consultation Clinic   (United States)

Author keywords

Chronic fatigue syndrome; Cytokine; Fatigue; GABA receptor modulator; Gene expression; Prostate cancer; Purinergic; QPCR

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; LYMPHOTOXIN; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ADRB2 GENE; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASIC3 GENE; CELL PROLIFERATION; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; CXCR4 GENE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; FATIGUE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LTA GENE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL GENE; MOOD DISORDER; MUSCLE CONTRACTION; MUSCLE STRENGTH; NR3C1 GENE; P2RX7 GENE; P2RY1 GENE; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SLEEP DISORDER; SOD2 GENE; TLR4 GENE; TNF GENE; UPREGULATION; VIPR2 GENE;

CHRONIC FATIGUE SYNDROME; CYTOKINE; FATIGUE; GABA-RECEPTOR MODULATOR; GENE EXPRESSION; PROSTATE CANCER; PURINERGIC; QPCR;

ADULT; AGED; CLUSTER ANALYSIS; DEPRESSION; DNA, COMPLEMENTARY; EXERCISE; FATIGUE; FATIGUE SYNDROME, CHRONIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PAIN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RNA, MESSENGER; SLEEP;

EID: 84888308674     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.08.008     Document Type: Article

References (54)

1. Barsevick A., Frost M., Zwinderman A., Hall P., Halyard M. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual. Life Res. 2010, 19:1419-1427.
2. Bower J.E. Fatigue, brain, behavior and immunity: summary of the 2012 Named Series on fatigue. Brain Behav. Immun. 2012, 26:1220-1223.
3. Bower J.E., Ganz P.A., Irwin M.R., Arevalo J.M., Cole S.W. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immun. 2011, 25:147-150.
4. Bower J.E., Ganz P.A., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism. J. Clin. Oncol. 2011, 29:3517-3522.
5. Brenu E.W., Van Driel M.L., Staines D.R., Ashton K.J., Ramos S.B., Keane J., Klimas N.G., Marshall-Gradisnik S.M. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J. Transl. Med. 2011, 9:81.
6. Cameron B.A., Bennett B., Li H., Boyle F., DeSouza P., Wilcken N., Friedlander M., Goldstein D., Lloyd A.R. Post-cancer fatigue is not associated with immune activation or altered cytokine production. Ann. Oncol. 2012, 23(11):2890-2895. 10.1093/annonc/mds108.
7. Capelli E, Zola R, Lorusso L, Venturini L, Sardi F, Ricevuti G. Chronic fatigue syndrome/myalgic encephalomyelitis: an update. Int. J. Immunopathol. Pharmacol. 2010, 23(4):981-989.
8. Chen J., Wang L., Zhang Y., Yang J. P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain. Acta Biochim. Biophys. Sin. 2012, 44:367-372.
9. Collado B., Carmena M.J., Sanchez-Chapado M., Ruiz-Vilaespesa A., Bajo A., Fernandez-Martinez A.B., Varga J.L., Schally A.V., Prieto J. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int. J. Oncol. 2005, 26:1629-1635.
10. de Raaf P.J., Sleijfer S., Lamers C.H., Jager A., Gratama J.W., van der Rijt C.C. Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer 2012, 118(23):6005-6011. 10.1002/cncr.27613.
11. Escalante C.P., Manzullo E.F. Cancer-related fatigue: the approach and treatment. J. Gen. Intern. Med. 2009, 24(Suppl. 2):S412-S4136.
12. Felger J.C., Cole S.W., Pace T.W., Hu F., Woolwine B.J., Doho G.H., Raison C.L., Miller A.H. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol. Med. 2012, 42:1591-1603.
13. Frampton D., Kerr J., Harrison T.J., Kellam P. Assessment of a 44 gene classifier for the evaluation of chronic fatigue syndrome from peripheral blood mononuclear cells. PLoS ONE 2011, 6(3):e16872.
14. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 1994, 121:953-959.
15. Furukawa T.A. Assessment of mood: guides for clinicians. J. Psychosom. Res. 2010, 68(June (6)):581-589.
16. Furusato B., Mohamed A., Uhlen M., Rhim J.S. CXCR4 and cancer. Pathol. Int. 2010, 60:497-505.
17. Galbraith S., Cameron B., Li H., Lau D., Vollmer-Conna U., Lloyd A.R. Peripheral blood gene expression in post-infective fatigue syndrome following from 3 different triggering infections. J. Infect. Dis. 2011, 204(10):1632-1640.
18. Grewen K.M., Light K.C. Plasma oxytocin is related to lower cardiovascular and sympathetic reactivity to stress. Biol. Psychol. 2011, 87:340-349.
19. Gupta S.C., Kim J.H., Kannappan R., Reuter S., Dougherty P.M., Aggarwal B.B. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp. Biol. Med. 2011, 236:658-671.
20. Hsiao C.P., Wang D., Kaushal A., Saligan L. Mitochondria-related gene Expression changes are associated with fatigue in patients with nonmetastatic prostate cancer receiving external beam radiation therapy. Cancer Nurs. 2013, 36:189-197.
21. Jager A., Sleijfer S., van der Rijt C.C. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?. Eur. J. Cancer 2008, 44(2):175-181.
22. Jaremka L.M., Fagundes C.P., Glaser R., Bennett J.M., Malarkey W.B., Kiecolt-Glaser J.K. Loneliness predicts pain, depression and fatigue: understanding the role of immune dysregulation. Psychoneuroendocrinology 2013, 38:1310-1317.
23. Jung S.J., Kim C.I., Park C.H., Chang H.S., Kim B.H., Choi M.S., Jung H.R. Correlation between chemokine receptor CXCR4 expression and prognostic factors in patients with prostate cancer. Korean J. Urol. 2011, 52:607-611.
24. Kang D., Lee K.M., Park S.K., Berndt S.I., Peters U., Reding D., Chatterjee N., Welch R., Chanock S., Huang W.Y., Hayes R.B. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1581-1586.
25. Kasina S., Macoska J.A. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol. Cell. Endocrinol. 2012, 351:249-263.
26. Kerr J.R. Gene profiling of patients with Chronic Fatigue Syndrome/Infectious encephalomyelitis. Curr. Rheumatol. Rep. 2008, 10(6):482-491.
27. Light A.R., Bateman L., Jo D., Hughen R.W., VanHaitsma T.A., White A.T., Light K.C. Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. J. Intern. Med. 2012, 271:64-81.
28. Light A.R., Hughen R.W., Zhang J., Rainier J., Liu Z., Lee J. Dorsal root ganglion neurons innervating skeletal muscle respond to physiological combinations of protons, ATP, and lactate mediated by ASIC, P2X, and TRPV1. J. Neurophysiol. 2008, 100:1184-1201.
29. Light A.R., White A.T., Hughen R.W., Light K.C. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J. Pain 2009, 10:1099-1112.
30. Light K.C., Vierck C.J. HPA axis and sympathetic influences on fibromyalgia, chronic fatigue and overlapping functional pain syndromes. Functional Pain Syndromes: Presentation and Pathophysiology 2009, 301-317. IASP Press, Seattle, WA. E. Mayer, M.C. Bushell (Eds.).
31. Morse M.D., McNeel D.G. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune response. Hum. Immunol. 2010, 7(5):496-504.
32. Nagakawa O., Junicho A., Akashi T., Koizumi K., Matsuda T., Fuse H., Saiki I. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. Oncol. Rep. 2005, 13:1217-1221.
33. Norheim K.B., Jonsson G., Omdal R. Biological mechanisms of chronic fatigue. Rheumatology 2011, 50:1009-1018.
34. Quiros I., Sainz R.M., Hevia D., Garcia-Suarez O., Astudillo A., Rivas M., Mayo J.C. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells. Int. J. Cancer 2009, 125:1497-1504.
35. Ramberg H., Eide T., Krobert K.A., Levy F.O., Dizeyi N., Bjartell A.S., Abrahamsson P.A., Tasken K.A. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate 2008, 68:1133-1142.
36. Reichling D.B., Levine J.D. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 2009, 32:611-618.
37. Ryan J.L., Carroll J.K., Ryan E.P., Mustian K.M., Fiscella K., Morrow G.R. Mechanisms of cancer-related fatigue. Oncologist 2007, 12(Suppl. 1):22-34.
38. Saiki T., Kawai T., Morita K., Ohta M., Saito T., Rokutan K., Ban N. Identification of marker genes for differential diagnosis of chronic fatigue syndrome. Mol. Med. 2008, 14:599-607.
39. Saylor P.J., Keating N.L., Smith M.R. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J. Gen. Intern. Med. 2009, 24(Suppl. 2):S389-S394.
40. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21(4):413-427.
41. Sharifi N., Hurt E.M., Thomas S.B., Farrar W.L. Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14:6073-6080.
42. Staines D.R., Brenu E.W., Marshall-Gradisnik S. Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: a role for phosphodiesterase inhibitors in treatment?. Neuropsychiatr. Dis. Treat. 2009, 5:81-89.
43. Storer T.W., Miciek R., Travison T.G. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J. Androl. 2012, 14:204-221.
44. Thomas R., Sharifi N. SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer. Mol. Cancer Ther. 2012, 11:87-97.
45. Thornton L.M., Andersen B.L., Blakely W.P. The pain, depression, and fatigue cluster in advanced breast cancer. Health Psychol. 2010, 29:333-337.
46. Toulme E., Tsuda M., Khakh B.S., Inoue K. On the role of ATP-gated P2X receptors in acute, inflammatory and neuropathic pain. Translational Pain Research: From Mouse to Man, Chapter 10, Series 2010, 235-249. CRC Press, Boca Raton, FL. L. Krueger, A.R. Light (Eds.).
47. Tsuda M., Tozaki-Saitoh H., Inoue K. Pain and purinergic signaling?. Brain Res. Rev. 2010, 63(1-2):222-232.
48. Wang M., Chen G.Y., Song H.T., Hong X., Yang Z.Y., Sui G.J. Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp. Ther. Med. 2011, 2:517-522.
49. Wang X.S., Shi Q., Williams L.A., Cleeland C.S., Komaki R.R., Mobley G.M., Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav. Immun. 2010, 24:968-974.
50. Wang X.S., Williams L.A., Krishnan S., Liao Z., Liu P., Mao L., Shi Q., Mobley G.M., Woodland J.F., Cleeland C.S. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav. Immun. 2012, 26:699-705.
51. White A.T., Light A.R., Hughen R.W., VanHaitsma T.A., Light K.C. Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls. Psychosom. Med. 2012, 74:46-54.
52. Wood L.J., Weymann K. Inflammation and neural signalling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr. Opin. Support. Palliat. Care 2013, 7(1):54-59.
53. Yunus M.B. Gender differences in fibromyalgia and other related syndromes. J. Gender Specific Med. 2002, 5(2):42-47.
54. Zheng H., Koo E.H. Biology and pathophysiology of the amyloid precursor protein. Mol. Neurodegener. 2011, 6(April (1)):27.